IMMUNEONCO-B (01541) surged over 12%, and as of press time, it was up 12.27% to HK$12.72, with a trading volume of HK$23.909 million.

On the news front, IMMUNEONCO's self-developed VEGF×PD-L1 bispecific antibody IMM2510 has recently submitted EOP2 communication requests to the National Medical Products Administration's Center for Drug Evaluation for two Phase III registration clinical trials targeting different types of lung cancer, marking its entry into a critical stage of clinical development.

According to reports, IMM2510 is developed based on the "mAb-Trap" technology platform and exerts anti-tumor effects through multiple mechanisms. Phase I clinical study results showed that IMM2510 achieved an objective response rate of 35.3% in treating advanced squamous non-small cell lung cancer patients who had received prior immunotherapy, with a disease control rate of 76.5% and a median progression-free survival of 9.4 months, demonstrating controllable safety profile. Phase II preliminary data showed significant efficacy when combined with chemotherapy as first-line treatment for NSCLC.

Based on these positive results, IMMUNEONCO plans to further validate IMM2510's efficacy and safety in Phase III clinical trials.

Notably, Guoyuan International pointed out that the company announced preliminary efficacy and safety data of IMM2510 monotherapy in advanced squamous non-small cell lung cancer (sq-NSCLC) patients at the 2025 World Lung Cancer Conference. The data came from the dose escalation and cohort expansion phases of the Phase I clinical study. IMM2510's announced monotherapy results showed an ORR of 35.3% and PFS of 9.4 months, demonstrating excellent clinical data and good safety profile.